A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816 · tracked via the Priya Life Science UK tracker

Sponsor

Annexon, Inc.

Phase

Phase 3

Started

2024-07-30

Last updated

2026-05-04

Condition(s) studied

Geographic Atrophy

Investigational drug(s) / intervention(s)

VonaprumentSham Administration

Vonaprument: Form: solution for injection; Route of Administration: IVT injection

Sham Administration: Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).

Study summary

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center. Exclusion Criteria: * Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye. NOTE: Other protocol-defined inclusion and exclusion criteria apply.

Primary outcome measure(s)

Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits — Baseline through Month 15

Trial sites (132)

Facility	City	Region
Retina Macula Institute of Arizona	Scottsdale	Arizona
Retina-Vitreous Associates Medical Group	Beverly Hills	California
Retinal Consultants of Orange County Clinical Research Institute Inc	Fullerton	California
Global Research Management	Glendale	California
Retina Consultants Medical Group	Modesto	California
Northern California Retina Vitreous Associates Medical Group, Inc.	Mountain View	California
Retinal Consultants Medical Group	Sacramento	California
Macula Retina Vitreous Research Institute	Torrance	California
Bay Area Retina Associates	Walnut Creek	California
Retina Consultants of Southern Colorado PC	Colorado Springs	Colorado
RSC Research, LLC	Denver	Colorado
Rand Eye Institute	Deerfield Beach	Florida
National Ophthalmic Research Institute	Fort Myers	Florida
Florida Retina Institute	Orlando	Florida
Fort Lauderdale Eye Institute	Plantation	Florida
Retina Group of Florida	Sarasota	Florida
Retina Vitreous Associates of Florida	St. Petersburg	Florida
East Florida Eye Institute	Stuart	Florida
Retina Associates of Florida	Tampa	Florida
Georgia Retina PC	Marietta	Georgia
Retina Consultants of Hawaii	‘Aiea	Hawaii
Retina Associates Ltd	Elmhurst	Illinois
University Retina	Oak Forest	Illinois
Springfield Clinic LLP	Springfield	Illinois
Wolfe Eye Clinic	West Des Moines	Iowa
Maine Eye Center	Portland	Maine
Retina Group of Washington	Chevy Chase	Maryland
Cumberland Valley Retina Consultants	Hagerstown	Maryland
Mid Atlantic Retina Specialists	Hagerstown	Maryland
Ophthalmic Consultants of Boston	Boston	Massachusetts
Retina Research Institute at New England Retina Consultants	Springfield	Massachusetts
Retina Consultants of Minnesota	Saint Louis Park	Minnesota
Sierra Eye Associates	Reno	Nevada
Envision Ocular, LLC	Bloomfield	New Jersey
Mid Atlantic Retina New Jersey	Cherry Hill	New Jersey
Vision Research Center Eye Associates of New Mexico	Albuquerque	New Mexico
Long Island Vitreoretinal Consultants	Hauppauge	New York
Asheville Eye Associates - Retina Division	Asheville	North Carolina
North Carolina Retina Associates	Cary	North Carolina
North Carolina Retina Associates	Wake Forest	North Carolina

+ 92 more sites — see the full list on the official registry below.

Other trials for the same condition

A Study in Adults With Geographic Atrophy Starting soon

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Recruiting

Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD Active, not recruiting

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study Active, not recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06510816 on ClinicalTrials.gov ↗ ← All trials in the UK